

NCI Cancer Imaging Informatics Workshop

September 26, 2002

Image-guided Therapy Center Washington University Saint Louis, Missouri

Walter R. Bosch, D.Sc.

Associate Director, Operations



IMAGE-GUIDED THERAPY CENTER Acknowledgements



4511 Forest Park, Suite 200
St. Louis, MO 63108

- | | |
|------------------------|-----------------------------|
| ✿ J. A. Purdy, Ph.D. | Director |
| ✿ Walter Bosch, D.Sc. | Assoc. Director, Operations |
| ✿ Jeff Michalski, M.D. | Assoc. Director, Clinical |
| ✿ Bill Straube, M.S. | Medical Physicist |
| ✿ John Matthews, D.Sc. | Computer Scientist |
| ✿ Sean O'Leary, M.S. | Programmer Analyst |

ITC HISTORY

- ✿ April 1992 3DQA Center established at WU-St. Louis to provide QA for RTOG 3DCRT clinical trials.
- ✿ May 1993 RTOG & 3DQA Center awarded NCI grant for Operation/ Statistical Center for prostate dose escalation study (3DOG).
- ✿ April 1999 NCI funded two Advanced Technology QA Centers
 - ✦ Advanced Technology QA Consortium
 - 3DQA Center → Image-guided Therapy Center (ITC)
 - RPC
 - QARC
 - RTOG
 - ✦ Resource Center for Emerging Technology (University of Florida)


NCI ADVANCED TECHNOLOGY QA CONSORTIUM



- ✦ In 2002, NCI has restructured the grant creating a single Advanced Technology Consortium (ATC) to support QA for advanced technology clinical trials (P.I. J. A. Purdy, Ph.D.)
- ✦ ATC consists of ITC, RCET, RPC, QARC, RTOG HQ Dosimetry
- ✦ New consolidated approach will eliminate duplication of effort and facilitate sharing of QA resources among cooperative groups.
- ✦ ATC will help ensure that appropriate and uniform QA procedures and criteria are developed for advanced technology trials.

Advanced Technology QA Consortium


Capitalizes on Infrastructure/Strengths of Existing National QA Programs



ITC and RCET provide a digital data exchange mechanism for existing QA Centers that serve various cooperative groups.


ITC's Original Challenge

- ❖ Define basic technical and clinical QA criteria for participation in RTOG 3DCRT protocols
 - ❖ Protocol development/nomenclature
 - ❖ Facility questionnaire
 - ❖ Dry run
- ❖ Develop treatment planning and verification (TPV) data exchange mechanism for participants
 - ❖ RTOG Data Exchange
 - ❖ DICOM RT Objects
- ❖ Develop QA program to review submitted TPV data
 - ❖ QA guidelines
 - ❖ Software tools





What's Special About 3D Treatment Planning/Verification (TPV) Data?

- ✿ Linkage of TPV data to clinical outcomes
 - ✦ Evaluating response statistics
 - ✦ Developing dose-response models.
- ✿ DVHs alone are not sufficient
 - ✦ Different dose distributions throughout an organ may lead to different expectations of toxicity for some organs.
 - ✦ Loss of Spatial Information in DVHs



White zones represent higher dose areas.



DIGITAL DATA EXCHANGE

TPV Data Submitted to ITC

✿ ITC has pioneered digital data exchange mechanisms of treatment planning-verification data for use in clinical trials.

- ✿ Patient Volumetric CT Data Set
- ✿ Contours: GTV, CTV, PTV, OAR's
- ✿ Volumetric 3-D Dose Distribution Data (Including Fractionation)
- ✿ Dose-Volume Histograms
- ✿ Beam Modality/Geometry Specification
- ✿ Digital Simulator and Portal Images












IMAGE-GUIDED THERAPY CENTER

Digital Data Submission



ITC Remote Case Review Tool

- ✦ Data Exchange
- ✦ CT Scan
- ✦ Organs at Risk Contours
- ✦ Target Volumes Contours
- ✦ Dose Prescription
- ✦ Dose uniformity



RTOG Advanced-Technology Protocols

RTOG Protocol	Site	Status	Approved Institutions	Accrued Cases*
9406	Prostate Ph I/II	Closed	53	1084
9311	Lung Ph I/II	Closed	26	180
9803	Brain (GBM) Ph I/II	Open	43	151
H-0022	Nasopharynx (IMRT) Ph I/II	Open	8	16
L-0117	Lung Ph I/II	Open	30	8
P-0126	Prostate Ph III	Open	57	14

* as of 9/16/2002


RTOG 94-06 3DCRT PROTOCOL

A Phase I/II Dose Escalation Study Using 3D Conformal Radiation Therapy for Adenocarcinoma of the Prostate

- **53 institutions credentialed to enroll patients on study.**
- **Dose Levels**
 - 68.4 Gy (1.8 Gy/fraction)
 - 73.8 Gy (1.8 Gy/fraction)
 - 79.2 Gy to GTV; 73.8 Gy to PTV (1.8 Gy/fraction)
 - 74.0 Gy to PTV (2 Gy/fraction)
 - 78.0 Gy to PTV (2 Gy/fraction)
- **Accrual History**
 - May 2, 1994 Activation Date
 - Oct 31, 2000 1084 Patients (study closed)

Grade 3+ Late Toxicities


Expected Observed



*Michalski, J.M., Purdy, J.A., Winter, K., et al.
 IJROBP 46(2):391-402, 2000.*

Linking Digital Treatment Planning Data to Outcomes

RTOG Protocol	Site	Status	Approved Institutions	Accrued Cases*
9406	Prostate Ph I/II	Closed	53	1084
9311	Lung Ph I/II	Closed	26	180
9803	Brain (GBM) Ph I/II	Open	43	151
H-0022	Nasopharynx (IMRT) Ph I/II	Open	8	16
L-0117	Lung Ph I/II	Open	30	8
P-0126	Prostate Ph III	Open	57	14



Early attempts

- Exchanges of Dose-Volume and Toxicity abstracts between RTOG HQ and ITC.
- M. Roach retrospective study using RCRT to contour penile bulb.

New (planned) initiative

- Dose-response modeling using RTOG 9406 data

OUTCOMES

- Normal-tissue complications
- Tumor control

Data Exchange Technical Workshops for RTP Vendors

- ✿ Mar 10, 1995, St. Louis: implementation of RTOG Data Exchange standard for participation in multi-institutional clinical trials.
- ✿ Sep 10-11, 1999, St. Louis: implementation of RTOG Data Exchange standard (emphasis on prostate brachy).
- ✿ March 16-17, 2001, St. Louis: implementation of DICOM 3.0 standard for participation in multi-institutional clinical trials.
- ✿ March 16, 2002, St. Louis: implementation of DICOM 3.0 standard for participation in multi-institutional clinical trials.

IMAGE-GUIDED THERAPY CENTER

WASHINGTON UNIVERSITY IN ST. LOUIS



SUMMARY AND CONCLUSION

- ✚ ITC has been in operation for nearly a decade and has provided RTOG the unique ability to conduct 3DCRT and IMRT multi-institutional clinical trials in which volumetric 3D treatment planning data can be collected, reviewed, analyzed, and linked to clinical outcomes.
- ✚ The **newly integrated ATC** is now in a position to extend these capabilities to a broad range of cooperative-group, advanced-technology clinical trials.